Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Jennifer M. Mitchell, Brian T. Anderson
Neuropsychopharmacology July 21, 2023 DOI: 10.1038/s41386-023-01656-7 via PubMed Central
Summary
AI-generated from the abstractOver the last five years, clinical research into psychedelic medicines has expanded rapidly, with data from a Phase 3 industry trial, a multicenter Phase 2 industry trial, and multiple early-phase trials now published in peer-reviewed journals. This narrative review summarizes recent findings and ongoing clinical trials involving various classes of psyche-manifesting substances that may help treat a broad range of conditions. The review also discusses methodological considerations, unique challenges, and next steps for research, emphasizing the experiential nature of these therapies.
Study at a glance
| Characteristics | Narrative review Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Mental health treatment Alternative medicine Psychiatric research |
| Citations | 47 |
| Key finding | Recent clinical trials suggest that psychedelic medicines may prove beneficial in treating a broad range of conditions, though further research is needed to address methodological challenges. |
Abstract
The clinical investigation of psychedelic medicines has blossomed over the last 5 years. Data from a Phase 3 industry trial and a multicenter Phase 2 industry trial, in addition to multiple early phase investigator-initiated and industry trials, have now been published in peer-reviewed journals. This narrative review summarizes both the recent data and the current clinical trials that are being conducted with various classes of "psyche-manifesting" substances, which may prove beneficial in the treatment of a broad range of conditions. Methodological considerations, unique challenges, and next steps for research are discussed in keeping with the uniquely "experiential" nature of these therapies.